Translating antenatal magnesium sulphate neuroprotection for infants born <28 weeks' gestation into practice: A geographical cohort study

Background Magnesium sulphate was introduced for fetal neuroprotection in Australia 2010. The aim of this study to determine how often antenatal magnesium is used currently and its association with cerebral palsy children born <28 weeks' gestation. Materials Methods Participants comprised all survivors gestational age the state Victoria 2016-17, earlier, 1991-92, 1997, 2005. Rates palsy, diagnosed at two years 2016-17 cohort, eight earlier cohorts, were compared across eras. Within proportions exposed determined, rates between those without exposure sulphate. Results Overall, present 6% (11/171) 12% (62/499) three eras (odds ratio (OR) 0.48, 95% confidence interval (CI) 0.25–0.94; P = 0.032). Data available 213/215 (99%) whom 147 (69%) received on 171 (80%) data. Cerebral 5/125 (4%) 6/46 (13%) not (OR 0.28, CI 0.08–0.96; 0.043). Conclusions Antenatal being translated into clinical practice infants gestation, but there room improvement. It associated lower survivors.